Dy1757

Manufactured by R&D Systems

Sourced in United States

The DY1757 is a laboratory instrument designed for the detection and analysis of specific biomolecules. It utilizes a specialized detection method to measure the presence and concentration of target analytes in sample solutions.

Automatically generated - may contain errors

Lab products found in correlation

Bs 380, by Mindray (4 mentions) Dy1750b, by R&D Systems (4 mentions) Dy206, by R&D Systems (1 mentions) Calprotectin reagents, by Mindray (1 mentions) Architect ci16200, by Abbott (1 mentions) Dy971, by R&D Systems (1 mentions) Ezglp1t 36k, by Merck Group (1 mentions) Dy1857, by R&D Systems (1 mentions) Victor nivo, by PerkinElmer (1 mentions) Dy1433, by R&D Systems (1 mentions) Dy1098, by R&D Systems (1 mentions) Cystatin c reagents, by Abbott (1 mentions) Odyssey clx scanner, by LI COR (1 mentions) Cw800, by LI COR (1 mentions)

11 protocols using dy1757

Urinary Biomarker Measurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

U-Cystatin C and U-Creatinine were analyzed on a BS380 instrument (Mindray, Shenzhen, China). The creatinine reagents were from Abbott Laboratories (Abbott Park, IL, USA) and the cystatin C reagent was from Gentian (Moss, Norway). The total coefficient of variation (CV) were 2.5% at 0.48 mg/L and 1.5% at 0.8 mg/L for U-Cystatin C and 1.4% at 8.5 mmol/L and 1.5% at 4.2 mmol/L for U-Creatinine. eGFR_Cr, in mL/min/1.73m², was estimated using the revised Lund-Malmö equation [18 (link)].
U-NGAL and U-KIM1 were analyzed were analyzed by commercial sandwich ELISA kits (DY1757 and DY1750B, R&D Systems, Minneapolis, MN, USA). The assays were calibrated against highly purified recombinant human peptides and the total CV of the assays were approximately 6%. All assays were performed blinded without knowledge of the clinical diagnosis.

Soveri I., Helmersson-Karlqvist J., Fellström B, & Larsson A. (2020). Day-to-day variation of the kidney proximal tubular injury markers urinary cystatin C, KIM1, and NGAL in patients with chronic kidney disease. Renal Failure, 42(1), 400-404.

+ Open protocol

+ Expand

Biomarker Measurement in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Calprotectin was measured on a Mindray™ BS-380 (Mindray Medical International,
Shenzhen, China) with calprotectin reagents from Gentian (Moss, Norway). The
instrument settings for the method were: sample volume = 3 µL, R1 volume =
200 µL and the R2 volume = 30 µL.
Plasma TNF-α, IL-6, NGAL and KIM-1/TIM-1 levels were analyzed with the commercial
sandwich ELISA kit, (DY210, DY206, DY1757, and DY1750 R&D Systems,
Minneapolis, MN). The total coefficient of variations for the assays were
approximately 7%.

Lipcsey M., Hanslin K., Stålberg J., Smekal D, & Larsson A. (2019). The time course of calprotectin liberation from human neutrophil granulocytes after Escherichia coli and endotoxin challenge. Innate Immunity, 25(6), 369-373.

+ Open protocol

+ Expand

Biomarker Assay Protocol for Kidney Injury Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

P‐Creatinine was analyzed on an Architect ci16200 (Abbott Laboratories). Creatinine and Urea in urine were measured on a Mindray™ BS‐380 (Mindray Medical International) with reagents from Abbott Laboratories. Urine Cystatin C was measured on the Mindray™ with reagents from Gentian. TIMP‐2, KIM‐1, and NGAL levels were analyzed with the commercial sandwich ELISA kit, (DY1757, DY971, and DY1750B, R&D Systems, Minneapolis, MN). The total coefficient of variations for the ELISAS were approximately 6%.
Mean + 2 standard deviations (SD) of values from healthy volunteers where used as cut offs for U‐Cystatin C¹² and TIMP‐2 and set accordingly to 0.414 mg/L for U‐Cystatin C and 7581 pg/mL for TIMP‐2. Urine albumin over 3 mg/mmol Creatinine was graded as microalbuminuria and over 30 mg/mmol Creatinine as severe albuminuria. Cut‐off values for U‐NGAL (100 ng/mL), and KIM‐1 (2.37 ng/mg Creatinine) were chosen from published values.¹³, ¹⁴

Luther T., Bülow‐Anderberg S., Larsson A., Rubertsson S., Lipcsey M., Frithiof R, & Hultström M. (2020). COVID‐19 patients in intensive care develop predominantly oliguric acute kidney injury. Acta Anaesthesiologica Scandinavica, 65(3), 364-372.

+ Open protocol

+ Expand

Multiplex Biomarker Quantification in Primates

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human serum LCN2, insulin, and GLP-1 were quantitated using commercially available ELISA kits and following the manufacturer’s instructions (#DY1757, R and D Systems, Minneapolis, MN;#90095, CrystalChem, Inc, Elk Grove Village, IL,; #EZGLP1T-36K, Merck, Burlington, MA, respectively). Monkey LCN2 and insulin were assayed with ELISA kits from LifeSpan BioSciences (#LS-F38530 and LS-F10306 respectively; Lifespan Biosciences, Inc, Seattle, WA) and leptin with an ELISA kit from Cusabio (#CSB-E14936Mk, Cusabio, Houston, TX). Circulating levels of primate CRP were determined using a commercially available ELISA kit using the manufacturer’s instructions (911CRP01P-96; Helica Biosystems, Inc, Santa Ana, CA). Blood chemistry was performed using a Heska Element DC Veterinary Chemistry Analyzer (Heska, Loveland, CO) at Columbia University’s Institute of Comparative Medicine Diagnostic Laboratory.

Petropoulou P.I., Mosialou I., Shikhel S., Hao L., Panitsas K., Bisikirska B., Luo N., Bahna F., Kim J., Carberry P., Zanderigo F., Simpson N., Bakalian M., Kassir S., Shapiro L., Underwood M.D., May C.M., Soligapuram Sai K.K., Jorgensen M.J., Confavreux C.B., Shapses S., Laferrère B., Mintz A., Mann J.J., Rubin M, & Kousteni S. (2020). Lipocalin-2 is an anorexigenic signal in primates. eLife, 9, e58949.

+ Open protocol

+ Expand

Measurement of Plasma LCN2 in Mice and Humans

Check if the same lab product or an alternative is used in the 5 most similar protocols

Whole blood was harvested from mice by cardiopuncture, and plasma was isolated using K₂EDTA tubes (BD 365974). Mouse plasma and CSF LCN2 concentrations were assayed by ELISA according to the manufacturer’s protocol (R&D Systems, Catalog # DY1857). Human plasma LCN2 concentrations were assayed by ELISA according to the manufacturer’s protocol (R&D Systems, Catalog # DY1757).

Olson B., Zhu X., Norgard M.A., Levasseur P.R., Butler J.T., Buenafe A., Burfeind K.G., Michaelis K.A., Pelz K.R., Mendez H., Edwards J., Krasnow S.M., Grossberg A.J, & Marks D.L. (2021). Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Nature Communications, 12, 2057.

+ Open protocol

+ Expand

NGAL Quantification in Plasma and Urine

Check if the same lab product or an alternative is used in the 5 most similar protocols

EDTA-plasma and urine levels of NGAL will be determined in duplicates using an in-house sandwich ELISA based on anti-NGAL antibodies and recombinant NGAL (#DY1757, R&D Systems, Minneapolis, USA). This test-kit has demonstrated high performance for precision, parallelism, recovery, selectivity, limit of quantitation, vulnerability to interference, hook effect and interassay agreement.58 59 (link) Measurements will be performed using a VICTOR Nivo microplate reader (PerkinElmer) and by an individual blinded to the sample IDs. Low-quality and high-quality control samples will be analysed in each analytical run. Assay range is 0.078–5 ng/mL, and the assay behaves linearly within the analytical range. In previous analyses, the limit of detection was <0.1 ng/mL based on NSB+3 SD. The within-assay coefficient of variation (CV) of standards, controls and unknown samples averaged less than 10%, and between-assay CV of standards and control samples averaged <15%.

Ravn E.J., Hasific S., Thomassen M., Hjortebjerg R., Bach Laursen K., Diederichsen A., Bistrup C, & Øvrehus K.A. (2023). Intravenous versus oral hydration to reduce the risk of postcontrast acute kidney injury after intravenous contrast-enhanced CT in patients with severe chronic kidney disease (ENRICH): a study protocol for a single-centre, parallel-group, open-labelled non-inferiority randomised controlled trial in Denmark. BMJ Open, 13(9), e074057.

+ Open protocol

+ Expand

Urine Biomarkers for Renal Pathology

Check if the same lab product or an alternative is used in the 5 most similar protocols

Urine galectin-3 binding protein levels were determined using an ELISA kit from MilliporeSigma (Cat # SPRCUS866, St Louis, MO, USA) according to the manufacturer’s instructions. The assay is specific for human Gal-3BP, has been validated for urine testing and can detect the analyte at a minimum detectable concentration of 0.08 ng/mL. Furthermore, we investigated other markers of renal pathology including, NGAL, OPN, KIM-1 and Gal-3 using commercial sandwich ELISAs (DY1757, DY1433, DY1750B and DY1154, R&D Systems, Minneapolis, MN, USA). Urine-albumin and urine-creatinine were determined on a Mindray BS-380 (Shenzhen Mindray Bio-medical Electronics, Shenzhen, China) using reagents from Abbott Laboratories (Abbott Park, IL, USA).
Urine-albumin/creatinine ratio (u-ACR) was calculated from the original values of the ratio determinants and expressed as mg/mmol. All biomarkers were analysed separately and values were normalized as concentration/u-creatinine levels.
All urine investigations were performed according to clinical routine at the Department of Clinical Chemistry at Uppsala University Hospital.

Faustini F., Idborg H., Fuzzi E., Larsson A., Lie W.R., Pötzsch S., Okitsu S.L., Svenungsson E, & Gunnarsson I. (2022). Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus. Lupus, 32(2), 252-262.

+ Open protocol

+ Expand

Biomarker Assays for ICU Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

We collected blood samples on study inclusion and twice daily thereafter until ICU discharge or start of renal replacement therapy. After centrifugation at 2000 rpm at 4 °C for 10 min, the supernatant plasma was stored at −80 °C.
Endostatin and NGAL were analyzed during 2013 using a commercially available enzyme-linked immunosorbent assay (ELISA) kit [DY1098 (endostatin) and DY1757 (NGAL), R&D Systems, Minneapolis, MN]. The assays had a total coefficient of variation (CV) of approximately 6 %. Cystatin C was measured with a particle-enhanced turbidimetric immunoassay on the Architect Ci8200 analyzer (Abbott Laboratories, Abbott Park, IL) with cystatin C reagents from Gentian (Moss, Norway).

Mårtensson J., Jonsson N., Glassford N.J., Bell M., Martling C.R., Bellomo R, & Larsson A. (2016). Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients. Annals of Intensive Care, 6, 6.

+ Open protocol

+ Expand

Measuring Intestinal Inflammation Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Measures of intestinal inflammation consisted of fCal (HK379-02; Hycult Biotech), fNeo (GWB-286F41; GenWay), and fLcn2 (DY1757; R&D Systems), performed according to the respective manufacturer’s instructions. Stools were diluted to 1:1000, 1:100, and 1:10 000, respectively. For fCal and fLcn2, we performed the first dilution of 1:50 with fecal extraction buffer (0.1 M Tris. HCL [8.0], 0.15 M NaCl, 1 M urea, 10 mM CaCl₂, 0.1 M citric acid monohydrate, 5 g/L BSA, and 0.25 mM thimerosal) and subsequent dilutions with reagent dilution buffer provided by the respective kits. For fNeo, we performed all dilutions with normal saline. All assays were performed in duplicate. Additional dilutions were performed for out-of-range optical density values until in-range values were obtained.

Duckworth L.A., Sutton K.A., Shaikh N., Wang J., Hall-Moore C., Holtz L.R., Tarr P.I, & Rubenstein R.C. (2024). Quantification of Enteric Dysfunction in Cystic Fibrosis: Inter- and Intraindividual Variability. The Journal of Pediatrics, 265, 113800.

+ Open protocol

+ Expand

Fecal Biomarkers for GI Disorders

Check if the same lab product or an alternative is used in the 5 most similar protocols

Faecal samples were blinded to clinical status and analysed for NGAL and calprotectin by enzyme-linked immunosorbent assay (ELISA). For NGAL, stool samples were diluted 1:5 (w/v), centrifuged and diluted to 1:500 and 1:1000 (1:6000 for aUC) (DY1757, R&D systems). Four samples (1 tCC, 1 IBS-D, 2 HC) were below range and set to half the detection limit (0.1 mg/kg). Calprotectin was analysed from the same faecal samples, diluted 1:50 (w/v) in Calpro Easy Extract by Calpro AS (Lysaker, Norway). Forty (5 aCC, 8 tCC, 15HC, 12 IBS-D) samples were below range and set to half the detection limit (12.5 mg/kg).

Bakke I., Walaas G.A., Bruland T., Røyset E.S., van Beelen Granlund A., Escudero-Hernández C., Thorsvik S., Münch A., Sandvik A.K, & Østvik A.E. (2021). Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis. Journal of Gastroenterology, 56(10), 914-927.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!